Sandoz to file for approval of aflibercept biosimilar
European Pharmaceutical Review
AUGUST 16, 2023
The confirmatory efficacy and safety study ( NCT04864834 ) demonstrated therapeutic equivalence between the biosimilar aflibercept and the reference biologic, Eylea®. Safety, immunogenicity, and pharmacokinetics results also confirmed no clinically meaningful difference between the products.
Let's personalize your content